For research use only. Not for therapeutic Use.
Anbenitamab（Cat No.:I042177）is an investigational monoclonal antibody that targets the protein B7-H3 (CD276), which is overexpressed in various cancers, including prostate, breast, and non-small cell lung cancer (NSCLC). B7-H3 is involved in immune evasion by tumor cells, making it a promising target for immunotherapy. By binding to B7-H3, anbenitamab aims to enhance immune system recognition and destruction of cancer cells. It is being studied in clinical trials for its potential to treat B7-H3-positive cancers, focusing on its safety, efficacy, and potential to improve outcomes in patients with solid tumors.
| Catalog Number | I042177 |
| CAS Number | 2367012-88-0 |
| Purity | ≥95% |
